Alexander N. Shoushtari, MD, discusses the significance of the findings from the first-in-human trial evaluating tebentafusp, a TCR–CD3 bispecific, in patients with advanced melanoma.
Alexander N. Shoushtari, MD, an assistant attending physician at Memorial Sloan Kettering Cancer Center, discusses the significance of the findings from the first-in-human trial evaluating tebentafusp (IMCgp100), a TCR—CD3 bispecific, in patients with advanced melanoma.
This TCR-CD3 bispecific was specifically engineered to mimic the human leukocyte antigen (HLA) molecule that that is found in everybody. Shoushtari says it is amazing to see tebentafusp working in the first-in-human trial, which has generated a lot of excitement among physicians.
The hope is that this agent will work for patients with uveal melanoma, but Shoushtari adds that the success with this mechanism of action can be broadly applied to other targets or those who don’t have this specific HLA type.